Hardman & Co Research
Hardman & Co Research: Open Orphan presenting at virtual Investor Forum on
9th July 2020
17-Jun-2020 / 09:32 GMT/BST
Hardman & Co Research: Open Orphan presenting at virtual Investor Forum on
9th July 2020
We are delighted to announce that Open Orphan will be presenting at our next
Investor Forum on Thursday 9th July. The Investor Forum connects investors
with companies looking for capital. Each company will present for 10-15
minutes, followed by an opportunity for Q&A.
Open Orphan (ORPH) is a publicly traded company on the London AIM and
Euronext Growth stock exchanges. The company was founded in 2017 with the
aim of becoming a leading specialist CRO pharmaceutical services business.
It has a focus on rare disease/orphan drugs, and is a world leader in the
provision of virology and vaccine challenge study services and viral
laboratory services. Open Orphan is comprised of two commercial specialist
CRO services businesses, hVIVO and Venn Life Sciences; and has offices in
London, Dublin, Paris and the Netherlands. The company consists of four
elements: a European clinical research organisation and consultancy; an
orphan drug services business; a Virtual Rep and Data Access Platform
consisting of physicians and key opinion leaders; and a Health Data Platform
to partner with Patient Advocacy Groups. It also provides digital data
platforms to support companies in research & development and
commercialisation.
https://www.hardmanandco.com/july-2020-virtual-investor-forum/ [1]
If you are interested in attending the virtual forum, you can register your
interest by clicking on the above link.
To contact us: Contact:
Hardman & Co Larissa Adams la@hardmanandco.com
35 New Broad Street
London +44 20 7194 7622
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter
@HardmanandCo
Hardman & Co Research can still be accessed for free after MiFID II. Please
click here [2] to read the statement.
About Hardman & Co: For the past 25 years Hardman has been producing
specialist research designed to improve investors' understanding of
companies, sectors, industries and investment securities. Our analysts are
highly experienced in their sectors, and have often been highly rated by
professional investors for their knowledge. Our focus is to raise companies'
profiles across the UK and abroad with outstanding research, investor
engagement programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this is
clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed
representative of Capital Markets Strategy Ltd and is authorised and
regulated by the Financial Conduct Authority; our FCA registration number is
600843. Hardman Research Ltd is registered at Companies House with number
8256259.
Our research is provided for the use of the professional investment
community, market counterparties and sophisticated and high net worth
investors as defined in the rules of the regulatory bodies. It is not
intended to be made available to unsophisticated retail investors. Anyone
who is unsure of their categorisation should consult their professional
advisors. This research is neither an offer, nor a solicitation, to buy or
sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
1071923 17-Jun-2020
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=dcba50ed3ab962de9d8b6463f196a3ef&application_id=1071923&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=1071923&site_id=vwd&application_name=news
(END) Dow Jones Newswires
June 17, 2020 04:32 ET (08:32 GMT)
© 2020 Dow Jones News
